



5.20.08

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	October 21, 2016
<b>Subject:</b>	SCIG	<b>Page:</b>	1 of 7

---

**Last Review Date:** June 16, 2022

---

## SCIG Immune Globulin (subcutaneous immunoglobulin)

### Description

SCIG Immune Globulin – Cutaquig, Cuvitru, Hizentra, Hyqvia, Xembify

### Background

Human immune globulin therapy is used for the treatment of immunodeficiency, prophylaxis of infectious diseases, and in the management of a variety of other inflammatory and autoimmune disorders. There are two main routes of administration: intravenous (IV) and subcutaneous (SC). A third route is intramuscular (IM), although this is uncommonly used, except for hyper-immune globulins (e.g., rabies immune globulin). There are also three different methods of administering immune globulin subcutaneously: traditional, facilitated subcutaneous, and subcutaneous rapid-push. Immune globulin products from human plasma were first used in 1952 to treat immune deficiency. Subcutaneous immunoglobulin (SCIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors (1).

### Regulatory Status

FDA-approved indications:

Cutaquig, Cuvitru, Hizentra, and Xembify are indicated as replacement therapies for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (2-5).

Hizentra is also indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (3).

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	October 21, 2016
<b>Subject:</b>	SCIG	<b>Page:</b>	2 of 7

---

Hyqvia is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (6).

#### Limitations of Use:

Safety and efficacy of chronic use of recombinant human hyaluronidase in Hyqvia have not been established in conditions other than PI (6).

Immune globulin use is associated with increased risk of thrombosis, particularly in the elderly and patients with risk factors such as cardiovascular disease, hypercoagulopathy, those on estrogen therapy, and patients with central venous catheters. Patients should be monitored carefully for signs and symptoms of thrombosis (2-6).

Immune globulin products have also been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs (2-6).

Other potential complications to monitor include the following: (2-6)

**Immunoglobulin A deficiency:** People with this condition have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

**Aseptic meningitis syndrome (AMS):** Rare occurrences of AMS have been reported in association with immune globulin treatment. AMS usually begins within several hours to 2 days following immune globulin treatment and is characterized by symptoms including severe headache, drowsiness, fever, photophobia, painful eye movements, muscle rigidity, nausea, and vomiting. AMS may occur more frequently in association with high-dose (2 g/kg) immune globulin treatment. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae.

**Bleeding complications:** Bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

**Severe reactions:** Severe reactions, such as anaphylaxis or angioneurotic edema, have been reported in association with immune globulin immunoglobulins, even in patients not known to be sensitive to human immunoglobulins or blood products.



---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	October 21, 2016
<b>Subject:</b>	SCIG	<b>Page:</b>	4 of 7

---

- mean age
  - 2) Selective IgA deficiency: IgA level < 7 mg/dL with normal IgG and IgM levels
  - 3) Selective IgM deficiency: IgM level < 30 mg/dL with normal IgG and IgA levels
  - 4) IgG subclass deficiency: IgG1, IgG2, or IgG3  $\geq 2$  SD below the mean age assessed on at least 2 occasions; normal IgG (total) and IgM levels, normal/ low IgA levels
  - 5) Specific antibody deficiency: normal IgG, IgA and IgM levels
- b. SCID (severe combined immunodeficiency disease) or agammaglobulinemia with **ONE** of the following
- i. Confirmed diagnosis by genetic or molecular testing
  - ii. Pretreatment IgG level <200mg/dL
  - iii. Absence or very low number of T cells (CD3 T cells < 300/microliter) or presence of maternal T cells in the circulation (SCID only)
- c. Wiskott-Aldrich syndrome, DiGeorge syndrome, or ataxia-telangiectasia (or other non SCID combined immunodeficiency) with **ALL** of the following:
- i. Confirmed diagnosis by genetic or molecular testing
  - ii. Documented history of recurrent bacterial and viral infections
  - iii. Impaired antibody response to pneumococcal vaccine
- d. CVID (common variable immunodeficiency disease) with **ALL** of the following:
- i. Documented history of recurrent bacterial and viral infections
  - ii. Impaired antibody response to pneumococcal vaccine
  - iii. Other causes of immune deficiency have been excluded (eg, drug induced, genetic disorders, infectious diseases such as HIV, malignancy)
  - iv. Pretreatment IgG level < 500mg/dL or  $\geq 2$  SD below the mean for the age

## Hizentra **ONLY**

- 2. Chronic inflammatory demyelinating polyneuropathy (CIDP)
  - a. 18 years of age or older
  - b. Previous treatment with immunoglobulin therapy (IVIG)
  - c. Prescriber agrees to initiate Hizentra one week after the last infusion of IVIG
  - d. Patient had significant improvement in disability and has maintained improvement while on previous immunoglobulin therapy (IVIG)

**Section:** Prescription Drugs

**Effective Date:** July 1, 2022

**Subsection:** Biologicals

**Original Policy Date:** October 21, 2016

**Subject:** SCIG

**Page:** 5 of 7

---

**AND ALL** of the following for **ALL** indications:

- a. Patients or caregivers have been instructed on how to monitor for signs and symptoms of thrombosis when self-administering the medication
- b. **NO** dual therapy with other immune globulin medications

## Prior – Approval *Renewal* Requirements

**Age**                      **Cutaquig, Cuvitru, Hizentra (PID), and Xembify:** 2 years and older  
                                 **Hizentra (CIDP), and Hyqvia:** 18 years and older

## Diagnoses

Patient must have **ONE** of the following:

1. Primary Immunodeficiency Disease (PID)
  - a. Patient has **ONE** of the following:
    - i. Hypogammaglobulinemia, IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency
    - ii. SCID (severe combined immunodeficiency disease) or Agammaglobulinemia
    - iii. Wiskott-Aldrich syndrome, DiGeorge syndrome, or ataxia-telangiectasia (or other non SCID combined immunodeficiency)
    - iv. CVID (common variable Immunodeficiency disease)

**AND ALL** of the following:

- a. Documented reduction in frequency of bacterial and viral infections since initiation
- b. IgG trough levels are monitored at least yearly and maintained at or above the lower range of normal for age
- c. The prescriber will re-evaluate the dose of the SCIG and reconsider a dose adjustment
- d. Patients or caregivers have been instructed on how to monitor for signs and symptoms of thrombosis when self-administering the medication
- e. **NO** dual therapy with other immune globulin medications

## Hizentra **ONLY**

2. Chronic inflammatory demyelinating polyneuropathy (CIDP)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	October 21, 2016
<b>Subject:</b>	SCIG	<b>Page:</b>	6 of 7

---

- a. 18 years of age and older
- b. CIDP symptoms have remained stable or improved since changing from previous immunoglobulin therapy (intravenous immunoglobulin)
- c. The prescriber will re-evaluate the dose of the SCIG and reconsider a dose adjustment
- d. Patients or caregivers have been instructed on how to monitor for signs and symptoms of thrombosis when self-administering the medication
- e. **NO** dual therapy with other immune globulin medications

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Duration** 12 months

### Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Human immune globulin therapy is used for the treatment of immunodeficiency, prophylaxis of infectious diseases, and in the management of a variety of other inflammatory and autoimmune disorders. Cutaquig, Cuvitru, Hizentra, and Xembify are subcutaneous immunoglobulin (SCIG) indicated as replacement therapies for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older. Hizentra is also indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Hyqvia is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults (1-6).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use SCIG while maintaining optimal therapeutic outcomes.

### References

1. UpToDate. Subcutaneous and intramuscular immune globulin therapy. Accessed on May 3, 2022.

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Biologicals	<b>Original Policy Date:</b>	October 21, 2016
<b>Subject:</b>	SCIG	<b>Page:</b>	7 of 7

2. Cuvitru [package insert]. Lexington, MA: Baxalta US Inc.; September 2021.
3. Hizentra [package insert]. Kankakee, IL: CSL Behring LLC; April 2021.
4. Xembify [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
5. Cutaquig [package insert]. Hoboken, NJ: Octapharma USA, Inc.; November 2021.
6. HyQvia [package insert]. Lexington, MA: Baxalta US Inc.; March 2021.

### Policy History

Date	Action
October 2016	Addition of Cuvitru to PA and the addition of Hyqvia and Hizentra to this PA
December 2016	Annual review
March 2017	Annual review
December 2017	Annual editorial review and reference update
April 2018	Addition of no dual therapy to criteria Addition of the diagnosis of CIDP to addition and continuation criteria for Hizentra only
June 2018	Annual review and reference update
November 2018	Annual review and reference update
March 2019	Annual editorial review and reference update. Updated CVID requirements per SME
June 2019	Addition of Cutaquig
September 2019	Annual review. Added references for PID diagnostic criteria per SME
October 2019	Addition of Xembify
December 2019	Annual review
March 2020	Annual review and reference update. Gammagard, Gamunex-C, and Gammaked to be kept on IVIG policy only per FEP
June 2020	Annual review
May 2021	Removal of the following CIDP renewal requirements: reduction of infections since initiation of therapy, and chronically stable patients having to taper and or withdraw treatment to determine if continued therapy is necessary
September 2021	Annual review
April 2022	Decreased age requirement for Cutaquig from 18 and older to 2 and older per PI update
June 2022	Annual review and reference update

### Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.**